about
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humansGenetic modifiers of non-alcoholic fatty liver disease progressionPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonPharmacogenomics of adverse drug reactionsThe human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variantsPooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE reviewGenetic regulation of warfarin metabolism and responseHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes.Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritisGene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver diseasePharmacogenetics of oral anticoagulants.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Pharmacogenetics of the major polymorphic metabolizing enzymes.Candidate gene case-control studies.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.Brief report: genetics of alcoholic cirrhosis-GenomALC multinational studyWarfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.Development of analytical technology in pharmacogenetic research.Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's diseasePNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease.The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.Pharmacogenetics of the cytochromes P450.The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card systemSignificance of the minor cytochrome P450 3A isoforms.A multi-factorial analysis of response to warfarin in a UK prospective cohortLimited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Flucloxacillin-induced liver injury.Nomenclature for alleles of the cytochrome P450 oxidoreductase gene.Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.Genome-wide association studies in pharmacogenomics.Drug-induced liver injury: past, present and future.Case definition and phenotype standardization in drug-induced liver injury.The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
P50
Q24304272-9EF5C2E1-533E-4161-A7D2-F70FA8442115Q26997101-6CD6342F-84A2-4090-A127-E5D33F1B25EFQ27006860-D816A8D6-65DE-4F4B-9380-B91624BC6F7CQ27015820-1B05C8CA-7873-491F-84F6-795A2889AF63Q28201500-6CD2AEE4-60C5-4BE2-B0F9-18CF9B75A888Q28214623-66F1858C-CA74-4CC8-9279-30D8C8E989A1Q28267140-3494E387-D26F-4C47-8851-7B47405FFA17Q29417159-69A1D74E-6C94-4CF5-A698-12BAF9C4F574Q30532640-CAAEC703-9A85-4E70-A842-4F74C1AC44E7Q33533986-89AD1845-A80A-428C-9129-192FA6BC888CQ33578668-2A17D453-C084-4D34-81EB-252AB1A26A4AQ33728918-1B97AFF4-1C31-4477-B80E-46A563CA05A8Q34194039-FC75B76B-1B1D-4D86-905C-0317C8C144E4Q34785862-1B377B12-4BA3-48C8-85D0-E9F613869BBCQ35067187-4E01DD05-E141-4EC7-9E92-5A1AF2C076DEQ35073279-F34B0E10-7E1E-4C83-9180-73CCC91F834AQ35085772-499AD35C-F7E0-4751-9DD8-179DAA18A1F3Q35438948-AC744921-1F0F-4322-9812-8AB0EB99F5B2Q35518733-53B5BECF-839D-440C-BD67-3774DFA97CECQ35545117-3ABFD0AC-8895-4A6B-B091-25ED594A5C00Q35597889-BB5009BC-49D6-49F6-9813-872C1F85720FQ35627657-8CC98FF0-AD42-4041-9C0B-6BBCCD1C30C9Q35640455-6BBFA544-50A6-48EF-A21E-F3C2D932C95CQ35812195-A6B76013-B0F9-4C2A-AFBF-3EE81B2EF935Q35900767-CB58826A-6392-4544-9EC4-F1E8A3425537Q35972693-6AE2A82F-E2C9-4F15-A091-064A6DF4EEA5Q36055087-AD7F51FA-3E6D-449F-8EB2-C7F7C87A5D95Q36055226-F423AEB3-AD73-4D2A-A3D5-85118CBED433Q36375323-8FBAFB3B-DEC3-4540-AD72-8905308933DEQ36433323-7CF72EC1-0D5A-4F6A-9A98-E2A6FE4AD15CQ36796350-4D453A77-821D-4F2C-8DD3-F52B56913C84Q37269762-CB4CC171-15D3-4D14-815B-AA06BFDFB06BQ37365498-CF99E908-40A4-4593-A3D0-E319642623F8Q37643487-57E6B620-ACBE-40FB-8B30-BB7CA6AA67CEQ37714294-8D5EBD61-4C23-4123-A2D0-AA4E19F2BB92Q37736444-3C82CB8B-8A71-4397-8C94-1699AC4E50DCQ37872195-9849FD34-C7BE-491C-9530-6DB15130AD78Q37877127-A5E10BD5-140C-446F-B5CA-CD556320E2F1Q38024911-3BF8B514-7136-411E-AD2F-7947381EE13CQ38042441-8D18EA70-8716-4EFC-AAC4-FA1309350A12
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ann K Daly
@ast
Ann K Daly
@en
Ann K Daly
@es
Ann K Daly
@nl
type
label
Ann K Daly
@ast
Ann K Daly
@en
Ann K Daly
@es
Ann K Daly
@nl
altLabel
Ann Daly
@en
prefLabel
Ann K Daly
@ast
Ann K Daly
@en
Ann K Daly
@es
Ann K Daly
@nl
P106
P21
P31
P496
0000-0002-7321-0629